The global retinal therapeutics market is prjoected to surpass $14 billion by 2024. Growth is being driven by:
Oxular’s development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and aged related macular degeneration, plus programs for rare and orphan conditions, including ocular cancers, and delivery of gene therapy.
Our treatments are engineered to access small spaces in the eye and to provide targeted drug distribution to tissues specifically involved in retinal diseases.
Oxular’s innovative technology enables sustained drug release, better delivery, and reduced side effects, while improving therapeutic effectiveness.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.